Navigation Links
Oramed Pharmaceuticals Expands Scientific Advisory Board With the Appointment of John Amatruda, M.D.

JERUSALEM, February 16, 2010 /PRNewswire-FirstCall/ --

- Dr. Amatruda is the Former Senior Vice President and Franchise Head of the Diabetes and Obesity Unit at Merck & Co.

Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB;, a developer of oral delivery systems, announced today that John M. Amatruda, M.D. has joined Oramed's Scientific Advisory Board, enhancing Oramed's talented and experienced scientific team.

Dr. Amatruda was the Senior Vice President and Franchise Head, Diabetes and Obesity at Merck Research Laboratories. He is board certified in internal medicine, endocrinology and metabolism and has a proven track record in academics and pharmaceutical discovery research and development, including several novel candidate compounds, INDs, translational studies, development programs and four NDAs.

In joining the Scientific Advisory Board, Dr. Amatruda will provide Oramed access to his extensive successful pharmaceutical industry experience in the development and approval of novel drugs. Additionally, his experience in licensing, structuring agreements and managing collaborations will prove invaluable to the Company.

"Dr. Amatruda is a very highly respected pharmaceutical executive and we are honored that he is joining our Scientific Advisory Board," said Nadav Kidron, Chief Executive Officer of Oramed. "His expertise and knowledge in the diabetes field will assist us in moving forward with the development of our product pipeline."

Dr. Amatruda commented that "it is a pleasure to join the Scientific Advisory Board of Oramed. Oramed's development of proprietary technology for the oral delivery of peptide pharmaceuticals will be an important advance in the treatment of many chronic diseases that require injectables, including diabetes."

Dr. Amatruda is joined on the Scientific Advisory Board by the following existing members: Derek LeRoith, Ph.D.; Nir Brazilai, M.D.; Ele Ferrannini, M.D., Ph.D.; and Avram Hershko, M.D., Ph.D.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.

For more information, please visit

Forward-looking statements

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements.

    Company and Investor Relation Contacts:
    Oramed Pharmaceuticals
    Tara Horn
    Cell: +972-54-334-318
    Office: +972-2-566-0001

SOURCE Oramed Pharmaceuticals Inc.

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Oramed Pharmaceuticals Announces Filing of Two Registration Statements
2. Oramed Pharmaceuticals was Chosen to Present Results of a GLP-1 Analog Oral Administration Study at the Diabetes Technology Societys Ninth Annual Meeting (November 5-7, 2009; San Francisco, CA)
3. Orameds Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the 2009 British Pharmaceutical Conference in Manchester, England
4. Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2009
5. Oramed Pharmaceuticals Announces Launch of Phase 2B Clinical Trials in South Africa of its Oral Insulin Capsule
6. Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA)
7. Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
8. Oramed Pharmaceuticals Chosen to Present Results of GLP-1 Analog Enteral Administration Study at the Diabetes Technology Societys Eighth Annual Meeting (November 13-15, 2008; Bethesda, Maryland)
9. Oramed Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository
10. /K I L L K I L L K I L L -- Oramed Pharmaceuticals Inc./
11. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
Post Your Comments:
(Date:10/9/2015)... , October 9, 2015 ... major players. --> India ... --> announces addition of 3 divalproex ... 2020 forecasts for global markets as well as ... along with analysis of major players. ...
(Date:10/9/2015)... 9, 2015  The Centers for Disease Control ... and Zoonotic Infectious Diseases, Office of Advanced Molecular ... a research collaboration to evaluate the performance of ... this research collaboration is to evaluate the utility ... health and infectious disease applications. This collaboration will ...
(Date:10/9/2015)... ClinicalKey Nursing debuts at ...   Elsevier , a world-leading provider of ... ClinicalKey for Nursing , a new clinical reference platform ... unique needs of nursing professionals. Attendees of the ANCC ... Oct. 7-9, will have the opportunity to demo ClinicalKey Nursing ...
Breaking Medicine Technology:
... plan for various study outcomes, MEXICO CITY, Aug. ... a new report, Anticipating the Results of PrEP,Trials, calling ... and advocates to prepare for initial,results - expected as ... drugs being tested for HIV prevention, known as PrEP ...
... is pleased,to announce the dosing of the first patient ... of AEG35156, a second generation antisense,therapeutic targeting XIAP, a ... The study, made possible, in part, by funding from ... Multicenter, Open-Label Study,of the X- Linked Inhibitor of Apoptosis ...
Cached Medicine Technology:
(Date:10/9/2015)... ... October 09, 2015 , ... ... welcoming individuals from all walks of life to save money on the high ... of $25 per month per medication, individuals and families can receive their medications ...
(Date:10/9/2015)... ... October 09, 2015 , ... ViewPoint Center, a teen mental health hospital ... mental illness, the stigma associated with mental illness causes many to hide away in ... importance of supporting teens with mental illness , providing teens with comprehensive diagnostic ...
(Date:10/9/2015)... Colorado (PRWEB) , ... October 09, 2015 , ... ... Station, one of the oldest and largest recreational dispensaries in Colorado, says the ... cannabis business is growing rapidly and maturing into a legitimate industry. , ...
(Date:10/9/2015)... (PRWEB) , ... October 09, 2015 , ... ... assisted living placement counseling, recently opened its newest office in Maryland – its ... care industry with a background as a project management technology consultant to many ...
(Date:10/9/2015)... ... ... Smanos was featured on NewsWatch as part of its monthly Tech Report, which features ... and special reporter for NewsWatch, conducted the review and shared with viewers how this ... age it’s more important than ever to keep homes and dorms safe and protected. ...
Breaking Medicine News(10 mins):
... of infamous psychological obedience study in 1960s , , MONDAY, ... as willing to follow orders to hurt others as they ... , In a replication of one of the most famous ... give what they believed were increasingly painful electric shocks to ...
... , WHAT: YEAR-IN-PREVIEW WEBINAR ... Wednesday, January 7, 2009 11:00 AM (U.S. Eastern Time) ... ENROLL: Please use the link below to register ... Millennium Research Group (MRG) complimentary webinar identifying the top 10 ...
... will be the subject of a policy forum sponsored ... January 13, 2009, from 3:00 p.m. until 4:30 p.m. ... Suites Resort, 5001 N. Scottsdale Road, Scottsdale, Arizona. This ... explore the relationship between health insurance coverage and access ...
... Mo., Jan. 5 The recent tragic death of Jett ... which he was diagnosed in early childhood. Kawasaki disease is ... the age of five. The disease occurs more often in ... and Korean descent. Although most children diagnosed with Kawasaki recover ...
... AUGUSTA, Ga. Just days after the first retinal ... start committing suicide and researchers believe their death may ... infection. , Understanding the cell death may also provide ... retina responds to assault, whether by infection or a ...
... WASHINGTON, Jan. 5 Despite a deepening recession, only ... raise less money this year than in 2008 said ... services for the poor and underinsured, according to a ... Philanthropy ( ).The overwhelming majority of AHP members ...
Cached Medicine News:
Incontinence Pessaries...
Incontinence Dish - Stress Incontinence with mild prolapse. Incontinence Dish with support - Stress Incontinence with mild prolapse and mild cystocele...
The Set comes with a cross reference chart that translates ring size into the correct size of other EvaCare pessaries. The Fitting Set can be disinfected in three ways: autoclaved, boiled or cold ste...
The donut pessary is designed for third degree prolapse as well as cystocele and rectocele. The soft donut can be compressed for insertion. It is available in seven sizes....
Medicine Products: